Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that Cabaletta Bio’s (Nasdaq: CABA) investigational CAR T cell therapy rese-cel (resecabtagene ...

Officials at Mytos, which is automating cell manufacturing, launched its automated contract development and manufacturing organization (CDMO), offering to overcome one of what they call regenerative ...

Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, and Cellares Corp, the first ...

A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. Cellares’ automated ...

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...